The global sleep disorder treatment drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027).  Sleep disorders are becoming more common across the globe, rising stress levels, a growing geriatric population, and increased awareness about various treatment choices for this disease are all likely to drive the market growth. According to the Narcolepsy Network, nearly one out of every 2,000 persons in the US suffers from a sleep disorder, which is contributing to the growth of the market.

The global sleep disorder treatment drugs market is anticipated to grow as the general public and governments become more aware of sleep problems. The growing number of people suffering from a variety of sleep disorders, including hallucinations, sleep paralysis, interrupted nocturnal sleep, insomnia, sleep apnea, narcolepsy, and circadian abnormalities, has drawn the attention of governments across the globe, pushing them to take action. Various networks, such as the National Center for Sleep Disorders Research, have run awareness campaigns to address the needs of those with serious or mild sleep disorders.

Additionally, key market players approval by government authority such as the FDA and commercialization of new drugs are also contributing to driving the market growth during the forecast period. For an instance, In March 2019, Sunosi (solriamfetol) was approved by the US Food and Drug Administration for the treatment of narcoleptic patients. However, a lower diagnosis rate, a lower treatment rate, and the adverse effects of sleep disorder medications may hinder demand for sleep disorder treatment drugs.

Among the application segment, insomnia is expected to dominate the global sleep disorders treatment market. The attributable factor for the growth of the segment is an increase in the prevalence of insomnia, which causes severe, uncontrollable daytime sleepiness as well as a loss of muscle tone. According to the National Institutes of Health, nearly 30% of the general population has sleep disruption, with approximately 10% experiencing daily functional impairment compatible with the diagnosis of insomnia. The factors expected to fuel this segment's growth during the forecast period include increased knowledge of the disease and available treatment choices, which will lead to early diagnosis of the condition. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Takeda Pharmaceutical Co., Ltd., Merck & Co., Inc., and Mylan NV, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Sleep Disorder Treatment Drugs Market Report by Segment

 By Drug Type  

• Benzodiazepines

• Nonbenzodiazepines

• Antidepressants

• Other 

By Application 

• Insomnia

• Sleep Apnea

• Narcolepsy

• Circadian Disorders

• Others

Global Sleep Disorder Treatment Drugs Market by Region